Advertisement

Der Onkologe

, Volume 24, Issue 12, pp 974–982 | Cite as

Aktueller Stand der Diagnostik und Therapie des nichtkleinzelligen Lungenkarzinoms (NSCLC) im Stadium III

  • Wilfried E. E. EberhardtEmail author
  • Martin Stuschke
  • Clemens Aigner
  • Michael Pogorzelski
Leitthema
  • 140 Downloads

Zusammenfassung

Basierend auf der ausgeprägten Heterogenität der Patientengruppen im Stadium III des nichtkleinzelligen Lungenkarzinoms („non-small-cell lung cancer“, NSCLC) – trotz der etwas differenzierteren neuen 8. Stadieneinteilung der Union Internationale Contre le Cancer (UICC)/International Association for the Study of Lung Cancer (IASLC) – wird eine zunehmend individualisierte Therapie dieser Patienten notwendig. Die initiale interdisziplinäre Einschätzung der Operabilität ist ein wesentlicher Faktor für die Therapieselektion. Die kombinierte simultane Chemostrahlentherapie bleibt für die Mehrzahl der Patienten im Stadium III die Standardbehandlung. Dieser Behandlung sollte sich aber – basierend auf den eindeutig und klinisch relevant positiven Ergebnissen der PACIFIC-Studie – eine konsolidierende Behandlung mit Durvalumab über 12 Monate bei positiver PD-L1-Expression im Tumor anschließen. Für die interdisziplinär als potenziell operabel eingeschätzten Patienten werden weiter multimodale Behandlungsprotokolle unter Einschluss der Operation den Standard darstellen. Aufgrund der positiven Datenlage für die Immuntherapie beim NSCLC in der Gruppe der inoperablen Patienten ergeben sich nun zwangsläufig auch in den lokal begrenzten Stadien hochrelevante Chancen für eine Integration der Checkpointinhibition in den Therapiealgorithmus, welche zukünftig detailliert im Rahmen von prospektiven klinischen Studien analysiert werden sollten.

Schlüsselwörter

Prognose Klinische Entscheidungsfindung Durvalumab Tumorklassifikation Radiochemotherapie 

Current status of diagnostic procedures and treatment in stage III non-small-cell lung cancer (NSCLC)

Abstract

Based on the considerable heterogeneity of patient subgroups in stage III non-small-cell lung cancer (NSCLC)—despite the slightly more differentiated 8th edition of the Union Internationale Contre le Cancer (UICC)/International Association for the Study of Lung Cancer (IASLC) staging classification—increasingly individualized treatment of these patients has become necessary. Initial interdisciplinary assessment of potential operability is a key factor for treatment selection. Standard treatment for the majority of stage III NSCLC patients is still concurrent chemoradiotherapy. However, based on the equivocal and clinically relevant positive results of the phase III PACIFIC trial, this treatment should be followed by consolidation therapy with durvalumab for 12 months in patients with proven PD-L1 expression in the tumor. In patients who are evaluated as potentially operable in interdisciplinary consensus, multimodality treatment protocols including definitive surgical resection of the tumor are still standard. Based on the positive data on immunotherapy in inoperable patients, there are now multiple interesting scenarios for integration of this new modality into the treatment of patients with localized disease, which should be carefully analyzed in well-designed prospective clinical trials.

Keywords

Prognosis Clinical decision making Durvalumab Neoplasm staging Chemoradiotherapy 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

W.E.E. Eberhardt weist auf folgende Beziehungen hin: Fortbildungsvorträge: BMS, MSD, Roche, Astra Zeneca, Novartis, Pfizer, Boehringer Ingelheim, Celgene, Hexal, Amgen, Lilly; Advisory Board Funktion: BMS, MSD, Roche, Astra Zeneca, Novartis, Pfizer, Boehringer Ingelheim, Celgene, Abbie, Bayer, Daichi Sankyo, Guardant Health, Lilly; Research Funding: Eli Lilly, BMS; Reisefinanzierung: Boehringer Ingelheim. M. Pogorzelski weist auf folgende Beziehungen hin: Fortbildungsvorträge: Boehringer Ingelheim, Merck Serono, MSD; Advisory Board Funktion: Boehringer Ingelheim, Merck Serono, MSD; Reisefinanzierung: Boehringer Ingelheim, BMS, MSD, Roche, Astra Zeneca, Novartis, Pfizer, Lilly, Teva. M. Stuschke und C. Aigner geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF Jr, Travis WD, Wu YL, IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions (2015) The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 10(7):990–1003CrossRefGoogle Scholar
  2. 2.
    Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions (2015) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 10(12):1675–1684CrossRefGoogle Scholar
  3. 3.
    Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions (2016) The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 11(1):39–51CrossRefGoogle Scholar
  4. 4.
    Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S, Panel Members (2015) 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 26(8):1573–1588 (Aug)CrossRefGoogle Scholar
  5. 5.
    Herder GJ, Kramer H, Hoekstra OS et al (2006) Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 24:1800–1806CrossRefGoogle Scholar
  6. 6.
    Dong X, Qiu X, Liu Q, Jia J (2013) Endobronchial ultrasound-guided transbronchial needle aspiration in the mediastinal staging of non-small cell lung cancer: a meta-analysis. Ann Thorac Surg 96:1502–1507CrossRefGoogle Scholar
  7. 7.
    De Leyn P, Dooms C, Kuzdzal J et al (2014) Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 45:787–798CrossRefGoogle Scholar
  8. 8.
  9. 9.
    Brunelli A, Charloux A, Bolliger CT et al (2009) ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 34:17–41CrossRefGoogle Scholar
  10. 10.
    Auperin A, Le Péchoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer. J Clin Oncol 28:2181–2190CrossRefGoogle Scholar
  11. 11.
    Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes EPROCLAIM (2016) Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced Nonsquamous non-small-cell lung cancer. J Clin Oncol 34(9):953–962CrossRefGoogle Scholar
  12. 12.
    Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187–199CrossRefGoogle Scholar
  13. 13.
    Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, De Petris L, Stitt L, Rodrigues G (2013) Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 85(2):444–450CrossRefGoogle Scholar
  14. 14.
    Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, Shi A, Jiang W, Xu Y, Zhou Z, Wang W, Chen D, Hui Z, Lv J, Zhang H, Feng Q, Xiao Z, Wang X, Liu L, Zhang T, Du L, Chen W, Shyr Y, Yin W, Li J, He J, Wang L (2017) Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol 28(4):777–783PubMedGoogle Scholar
  15. 15.
    Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, Le Chevalier T, Collaborative Group (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(21):3552–3559CrossRefGoogle Scholar
  16. 16.
    Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, Peters S (2013) ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi89–vi98CrossRefGoogle Scholar
  17. 17.
    Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR, Cancer and Leukemia Group B (2007) Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25(13):1698–1704CrossRefGoogle Scholar
  18. 18.
    Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, Dickgreber N, Vaissiere N, De Almeida C, Edlich B, Fietkau R (2016) GILT—A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol 192(4):216–222CrossRefGoogle Scholar
  19. 19.
    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators (2017) Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 377(20):1919–1929CrossRefGoogle Scholar
  20. 20.
    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M, PACIFIC Investigators (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med.  https://doi.org/10.1056/NEJMoa1809697 CrossRefPubMedGoogle Scholar
  21. 21.
    Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC, KEYNOTE-189 Investigators (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078–2092CrossRefGoogle Scholar
  22. 22.
    Pless M, Stupp R, Ris HB et al (2015) Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet 386(9998):1049–1056CrossRefGoogle Scholar
  23. 23.
    Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374(9687):379–386CrossRefGoogle Scholar
  24. 24.
    Eberhardt WE, Pöttgen C, Gauler TC et al (2015) Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol 33(35):4194–42018CrossRefGoogle Scholar
  25. 25.
    Pöttgen C, Eberhardt W, Grannass A, Korfee S, Stüben G, Teschler H, Stamatis G, Wagner H, Passlick B, Petersen V, Budach V, Wilhelm H, Wanke I, Hirche H, Wilke HJ, Stuschke M (2007) Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol 25(31):4987–4992CrossRefGoogle Scholar
  26. 26.
    De Ruysscher D, Dingemans AC, Praag J, Belderbos J, Tissing-Tan C, Herder J, Haitjema T, Ubbels F, Lagerwaard F, El Sharouni SY, Stigt JA, Smit E, van Tinteren H, van der Noort V, Groen HJM (2018) Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell lung cancer: a randomized phase III NVALT-11/DLCRG-02 study. J Clin Oncol 36(23):2366–2377CrossRefGoogle Scholar
  27. 27.
    Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H (2011) Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 29(3):272–278.  https://doi.org/10.1200/JCO.2010.29.1609 (Erratum in: J Clin Oncol. 2011 Aug 10;29(23):3204)CrossRefPubMedGoogle Scholar
  28. 28.
    Sun A, Hu C, Gore E, Wong S, Videtic G, Dutta S, Suntaralingham M, Chen Y, Gaspar L, Choy H (2018) 10-year updated analysis of NRG oncology/RTOG 0214: a phase III comparison of PCI versus observation in patients with LA NSCLC. Proc WCLC 2019; abstract OA 01.01.Google Scholar
  29. 29.
    Exner JP, Nadjm E, Gauler T et al (2018) Long-term survival and survivorship program of lung cancer patients—B: implications for follow-up and surveillance. Oncol Res Treat 41(suppl 1 abstr 486):109–110Google Scholar
  30. 30.
    Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, CANTOS Trial Group (2017) Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390(10105):1833–1842CrossRefGoogle Scholar
  31. 31.
    Peters S et al (2018) Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first-line chemo-RT regimen in unresectable locally advanced NSCLC. The ETOP NICOLAS phase-II trial. J Clin Oncol 36(15S):440s (abstr 8510)Google Scholar
  32. 32.
    Provencio M, Nadal E, Insa A, Garcia Campelo R, Huidobro G, Domne M, Majem M, Rodriguez-Abreu D, Calvo V, Massutti B (2018) Phase-II study of neoadjuvant chemo/immunotherapy for resectabel stages IIIA NSCLC.: NADIM study SLCG. Proc. WCLC. (Abstr OA 01.05)Google Scholar
  33. 33.
    Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O’Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L (2018) Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 378(22):2093–2104CrossRefGoogle Scholar
  34. 34.
    Rebmann V, Eberhardt WEE, Rizvi N, Antonia SA, Planchard D, Cappuzzo F, Mazières J, Zalcman G, Lena H, Wolf J, Horn L, Stinchcombe T, Dy G, Blackwood-Chirchir A, Jin C, Geese WJ, Ramalingam SS (2017) Soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients (pts) with advanced, refractory squamous (SQ) NSCLC treated with nivolumab (NIVO): CheckMate 063. Proc AACR 2017: Abstr CT 126/7.CrossRefGoogle Scholar
  35. 35.
    Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JMM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG (2018) Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol S1556-0864(18)33129-0.  https://doi.org/10.1016/j.jtho.2018.09.017 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Wilfried E. E. Eberhardt
    • 1
    Email author
  • Martin Stuschke
    • 2
  • Clemens Aigner
    • 3
  • Michael Pogorzelski
    • 1
  1. 1.Innere Klinik (Tumorforschung) und Ruhrlandklinik, Westdeutsches TumorzentrumUniversitätsmedizin EssenEssenDeutschland
  2. 2.Klinik für StrahlentherapieUniversitätsmedizin EssenEssenDeutschland
  3. 3.Klinik für Thoraxchirurgie und Thorakale EndoskopieUniversitätsmedizin EssenEssenDeutschland

Personalised recommendations